Memoplant, 120 mg 30 pcs

Pharmacotherapeutic group

An angioprotective agent of plant origin.

ATX code

N06DX02

/p>

Pharmacological properties

Pharmacodynamics

It increases the body’s resistance to hypoxia, especially brain tissue.

Enhances cerebral and peripheral blood circulation, improves blood rheology. It has a dose-dependent regulatory effect on the vascular wall, dilates small arteries and increases the tone of veins. Prevents the formation of free radicals and lipid peroxidation of cell membranes. It improves metabolism in organs and tissues, promotes the accumulation of macroergies in cells, increases the utilization of oxygen and glucose, and normalizes mediator processes in the central nervous system.

Pharmacokinetics

Assimilation

After oral administration, the bioavailability of the terpenlactones (ginkgolide A, ginkgolide B, and bilobalide) is 80% for ginkgolide A, 88% for ginkgolide B, and 79% for bilobalide.

Distribution

. Peak plasma concentrations were 16-22 ng/mL for ginkgolide A, 8- 10 ng/mL for ginkgolide B, and 27-54 ng/mL for bilobalide after administration in tablet form. Binding to plasma proteins is: 43% for ginkgolide A, 47% for ginkgolide B, and 67% for bilobalide.

Evolution

The elimination half-life is 3.9 hours (ginkgolide A), 4-6 hours (ginkgolide B) and 2-3 hours (bilobalide).

Indications

Active ingredient

Composition

(per tablet)

Active ingredient:

Ginkgo biloba leaf extract dry* EGb 761®** (35-67:1), extractant: 60% acetone, standardized for 29.4 mg ginkgoflavonglycosides and 7.2 mg terpenlactones (3.36-4.08 mg ginkgolides A,B, C and 3.12-3.84 mg bilobalides) 120.00 mg.

Core Auxiliary Components:

Lactose monohydrate 68.25 mg; colloidal silica 3.00 mg; microcrystalline cellulose 163.5 mg; corn starch 15.00 mg; croscarmellose sodium 15.00 mg; magnesium stearate 5.250 mg.

Shell excipients:

Hypromellose 11.5728 mg; macrogol 1500 5.7812 mg; foaming emulsion SE2 0.0150 mg ***; titanium dioxide (E 171) 1.6260 mg; iron oxide red (E 172) 1.3000 mg; talc 0.7200 mg.

Dry extract obtained from the leaves of Ginkgo biloba (Ginkgo biloba L.), family: Ginkgoaceae

**Ginkgo biloba extract (manufacturer Schwabe Extracta GmbH & Co.KG , Germany or Wallingstown Company Ltd. / Cara Partners, Ireland) EGb 761® (number given to the extract by the manufacturer).

***articles Eur.F. on the individual components of the SE2 foaming emulsion

How to take, the dosage

Interaction

Caution should be exercised when taking the drug in patients who regularly take acetylsalicylic acid, anticoagulants (direct and indirect). Single cases of bleeding have been reported in patients concomitantly taking anticoagulants; a causal relation of these bleedings to administration of Ginkgo biloba has not been confirmed.

The concomitant use of Ginkgo biloba products with efavirenz is not recommended because its concentration in plasma may decrease due to induction of CYP3A4 cytochrome by Ginkgo biloba extract.

Special Instructions

Please pay attention! All prescriptions must be strictly adhered to.

Before treating with EGb 761® Ginkgo Biloba Extract, you should first consult any pre-existing medical conditions to determine whether the symptoms are related to those conditions.

The recommended doses should not be exceeded. Discontinue use if a hypersensitivity reaction develops. Before

surgical interventions, it is necessary to inform the doctor about taking the drug. If dizziness and tinnitus occur frequently, a physician should be consulted. In case of sudden worsening or loss of hearing, you should immediately consult a physician. Patients with bleeding disorder (hemorrhagic diathesis) and patients receiving anticoagulant therapy should consult a physician before starting therapy with the drug. Against the background of using the drug, epileptic seizures may occur in patients suffering from epilepsy. Caution is recommended when co-administering drugs metabolized by cytochrome P450, including SUR3A4 (see section “Interaction with other medicinal products”).

Because there is evidence that products containing Ginkgo biloba leaf extract may decrease blood clotting, the drug should be discontinued 3 to 4 days before surgical intervention.

The drug contains lactose. Patients with hereditary lactose intolerance, lactase deficiency or glucose-galactose malabsorption should not take the drug.

Influence on driving, operating machinery

. During the period of using the drug care must be taken when performing potentially hazardous activities requiring high concentration and quick psychomotor reactions (driving vehicles, operating moving machinery, work of dispatcher, operator).

Synopsis

Contraindications

Side effects

By frequency of occurrence, side effects are classified as follows:

Very common (≥1/10), common (≥1/100 to < 1/10), infrequent (≥1/1000 to < 1/100), rare (≥1/10000 to < 1/1000), very rare, including individual reports (< 1/10000), frequency not determined.

Immune system disorders

Hypersensitivity, urticaria. Frequency has not been established.

Nervous system disorders

Dizziness, headache. Frequency has not been determined.

Gastrointestinal disorders

Rarely: nausea, abdominal pain, diarrhea, dyspepsia.

Skin and subcutaneous tissue disorders

Allergic reactions such as eczema, itching, rash. Frequency has not been determined.

Vascular disorders

Bleeding from certain organs. Frequency has not been established.

If you experience or worsen the side effects listed in the instructions, or if you notice any other side effects not listed in the instructions, tell your doctor.

Overdose

Pregnancy use

Similarities